10.04

1.86% -0.19

After Hours: 10.03 -0.010 -0.10%

Cartesian Therapeutics Inc (RNAC)

Overview News Price History Option Chain Financials Discussions Forecast

Cartesian Therapeutics Inc stock is traded at $10.04, with a volume of 163.85K. It is down -1.86% in the last 24 hours and up +23.49% over the past month. Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.

Previous Close:

$10.23

Open:

$10.35

24h Volume:

163.85K

Relative Volume:

0.63

Market Cap:

$303.76M

Revenue:

$1.78M

Net Income/Loss:

$-151.77M

P/E Ratio:

-1.7316

EPS:

-5.7981

Net Cash Flow:

$-77.37M

1W Performance:

+13.57%

1M Performance:

+23.49%

6M Performance:

+44.88%

1Y Performance:

-8.39%

1-Day Range:

$10.00

$10.69

1-Week Range:

$8.745

$10.87

52-Week Range:

$5.60

$11.80

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name

Cartesian Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

301-348-8698

Address

7495 NEW HORIZON WAY, FREDERICK

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

RNAC's Discussions on Twitter

Compare RNAC vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNAC Cartesian Therapeutics Inc	10.04	309.51M	1.78M	-151.77M	-77.37M	-5.7981
VRTX Vertex Pharmaceuticals Inc	548.05	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	834.04	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,039.78	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.13	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	209.46	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-09-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-09-25	Initiated	Wedbush	Outperform
Dec-19-24	Initiated	BTIG Research	Buy
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform
May-24-24	Initiated	Mizuho	Buy
Apr-23-24	Reiterated	H.C. Wainwright	Buy
Apr-23-24	Initiated	Leerink Partners	Outperform
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform
Jun-14-22	Reiterated	Needham	Buy
Jun-06-22	Initiated	SVB Leerink	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Jan-26-21	Upgrade	Mizuho	Neutral → Buy
Oct-01-20	Downgrade	Mizuho	Buy → Neutral
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy
Mar-30-17	Reiterated	UBS	Buy

View All

Cartesian Therapeutics Inc Stock (RNAC) Latest News

Aug 19, 2026

Cartesian (RNAC) Earnings Report: EPS Comes in Above Forecast in the Latest Reading; Market Reaction: The Stock Ends Up 14.02% in the Latest SessionEarnings Quality Score - vinanet.vn

Aug 19, 2026

Cartesian Therapeutics Inc. (NASDAQ: RNAC) Share Price, RNAC Stock News, RNAC Share Price & Updates - Kalkine

Aug 19, 2026

Cartesian (RNAC) Results at a Glance: EPS Prints Above Forecast in the Current Update; Latest Reaction: The Stock Gains 9.78% in the Latest ReadingCore Business Growth - vinanet.vn

Aug 19, 2026

Cartesian (RNAC) Q2 2026 Earnings: The Bottom-Line Figure Beats Its Comparison in the Latest Session; Closing Reaction: The Stock Gains 0.22% at the CloseMid-Term Outlook - vinanet.vn

Aug 19, 2026

Aug 18, 2026

RNAC Reiterated by Wedbush -- Rating Maintained at Outperform - GuruFocus

Aug 18, 2026

Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Aug 18, 2026

Aug 13, 2026

Cartesian Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | RNAC | US8162123025 - marketscreener.com

Aug 13, 2026

Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics - Stock Titan

Aug 13, 2026

Aug 11, 2026

Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Aug 11, 2026

HC Wainwright Analysts Lower Earnings Estimates for RNAC - MarketBeat

Aug 11, 2026